Arctic Bioscience Past Earnings Performance

Past criteria checks 0/6

Arctic Bioscience's earnings have been declining at an average annual rate of -20%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 16.1% per year.

Key information

-20.0%

Earnings growth rate

-7.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate16.1%
Return on equity-20.6%
Net Margin-151.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Arctic Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:9TD Revenue, expenses and earnings (NOK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2432-48250
31 Mar 2433-47240
31 Dec 2334-46240
30 Sep 2336-43240
30 Jun 2339-40250
31 Mar 2337-37230
31 Dec 2234-34220
30 Sep 2229-35180
30 Jun 2224-36150
31 Mar 2223-39160
31 Dec 2122-43170
30 Sep 2123-38150
30 Jun 2125-34130
31 Mar 2123-28120
31 Dec 2021-23110
31 Dec 1930-460
31 Dec 1825-260
31 Dec 1718-250

Quality Earnings: 9TD is currently unprofitable.

Growing Profit Margin: 9TD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 9TD is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.

Accelerating Growth: Unable to compare 9TD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9TD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 9TD has a negative Return on Equity (-20.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies